Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by C2N Diagnostics, LLC

C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias
From C2N Diagnostics, LLC
Via Business Wire
Samsung Invests in C2N Diagnostics
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
From C2N Diagnostics, LLC
Via Business Wire
Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health
From C2N Diagnostics, LLC
Via Business Wire
JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care
From C2N Diagnostics, LLC
Via Business Wire
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
From C2N Diagnostics, LLC
Via Business Wire
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
From C2N Diagnostics, LLC
Via Business Wire
Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology
From C2N Diagnostics, LLC
Via Business Wire
On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF
From C2N Diagnostics, LLC
Via Business Wire
Real-World Evidence Shows Healthcare Providers Use C2N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions
From C2N Diagnostics, LLC
Via Business Wire
C2N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkers in the Diagnosis of Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
C2N Diagnostics Introduces the PrecivityAD2™ Blood Test
From C2N Diagnostics, LLC
Via Business Wire
C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments
From C2N Diagnostics, LLC
Via Business Wire
Independent Research Finds Underlying Method for C2N’s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses
From C2N Diagnostics, LLC
Via Business Wire
C2N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices
From C2N Diagnostics, LLC
Via Business Wire
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
From C2N Diagnostics, LLC
Via Business Wire
Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis
From C2N Diagnostics, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.